title: Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.
abstract: Dexamethasone is a key component in the treatment of childhood acute lymphoblastic leukaemia (ALL). Despite playing a key role in the improved survival of ALL over several decades, intensification of dexamethasone therapy has also contributed to the increased toxicity associated with treatment, which is now seen to be at unacceptable levels given the favourable disease prognosis. Therefore the focus for treatment is now shifting towards reducing toxicity whilst maintaining current survival rates. As approximately 50% of patients were successfully treated on less intensive protocols of the 1980s, it has been questioned whether therapy intensification is necessary in all patients. Furthermore, there remains a subset of children who are still not cured of their disease. New strategies are therefore needed to identify patients who could benefit from dose reduction or intensification. However, adjusting a potentially life threatening therapy is a challenging task, particularly given the heterogeneous nature of ALL. This review focuses on the potential for patient stratification based on our current knowledge of dexamethasone pharmacokinetics, pharmacogenetics and the action of dexamethasone at the cellular level. A carefully designed, combined approach is needed if we are to achieve the aim of improved personalization of dexamethasone therapy for future patients.
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
authors.forename: Rosanna K
authors.initials: RK
authors.lastname: Jackson
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
authors.forename: Julie A E
authors.initials: JA
authors.lastname: Irving
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
authors.forename: Gareth J
authors.identifier: http://orcid.org/0000-0002-1897-8678
authors.initials: GJ
authors.lastname: Veal
mesh_terms: D003907:Dexamethasone / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D057285:Precision Medicine / Q000379:methods*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
chemical_list: D003907:Dexamethasone
keywords: acute lymphoblastic leukaemia; dexamethasone; personalized medicine; pharmacology; toxicity